Where is Sativex® available?
In April 2005 GW received regulatory approval for Sativex® in Canada for symptomatic relief of neuropathic pain. In August 2007, Health Canada approved Sativex® as adjunctive analgesic treatment in patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain. Both approvals were secured under the Notice of Compliance with Conditions (NOC/c) policy. Sativex® is marketed in Canada exclusively by Bayer Healthcare.
